Evidence map›Paper›PMID 28676103›Full record

ArticleBMC medicine2017

Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition.

Julie A Schmidt, Georgina K Fensom, Sabina Rinaldi, Augustin Scalbert, Paul N Appleby, David Achaintre, Audrey Gicquiau, Marc J Gunter, Pietro Ferrari, Rudolf Kaaks and 26 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Characteristics of Cancer Epidemiology Studies That Employ Metabolomics: A Scoping Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 19 institutions in 8 countries.

Julie A SchmidtCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK. julie.schmidt@ceu.ox.ac.uk.
Georgina K FensomCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
Sabina RinaldiInternational Agency for Research on Cancer, 69372, Lyon, CEDEX 08, France.
Augustin ScalbertInternational Agency for Research on Cancer, 69372, Lyon, CEDEX 08, France.
Paul N ApplebyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
David AchaintreInternational Agency for Research on Cancer, 69372, Lyon, CEDEX 08, France.
Audrey GicquiauInternational Agency for Research on Cancer, 69372, Lyon, CEDEX 08, France.
Marc J GunterInternational Agency for Research on Cancer, 69372, Lyon, CEDEX 08, France.
Pietro FerrariInternational Agency for Research on Cancer, 69372, Lyon, CEDEX 08, France.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Foundation under Public Law, DE-69120, Heidelberg, Germany.
Tilman KühnDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Foundation under Public Law, DE-69120, Heidelberg, Germany.
Anna FloegelDepartment of Epidemiology, German Institute of Human Nutrition (DIfE) Potsdam-Rehbrücke, DE-14558, Nuthetal, Germany.
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition (DIfE) Potsdam-Rehbrücke, DE-14558, Nuthetal, Germany.
Antonia TrichopoulouHellenic Health Foundation, GR-11527, Athens, Greece.
Pagona LagiouHellenic Health Foundation, GR-11527, Athens, Greece.
Eleutherios AnifantisHellenic Health Foundation, GR-11527, Athens, Greece.
Claudia AgnoliEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133, Milano, Italy.
Domenico PalliCancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, 50134, Florence, Italy.
Morena TrevisanCancer Epidemiology Unit-CERMS, Department of Medical Sciences, University of Turin, 10126, Turin, Italy.
Rosario TuminoCancer Registry and Histopathology Unit, "Civic-M.P.Arezzo" Hospital, ASP 97100, Ragusa, Italy.
H Bas Bueno-de-MesquitaDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK.
Antonio AgudoUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, 08908, L'Hospitalet de Llobregat, Barcelona, Spain.
Nerea LarrañagaPublic Health Division of Gipuzkoa, Regional Government of the Basque Country, 20014, Donostia-San Sebastián, Spain.
Daniel Redondo-SánchezCIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Aurelio BarricarteCIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
José Maria HuertaCIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
J Ramón QuirósPublic Health Directorate, 33006, Asturias, Spain.
Nick WarehamMRC Epidemiology Unit, University of Cambridge, CB2 0SR, Cambridge, UK.
Kay-Tee KhawSchool of Clinical Medicine, University of Cambridge, CB2 2QQ, Cambridge, UK.
Aurora Perez-CornagoCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
Mattias JohanssonInternational Agency for Research on Cancer, 69372, Lyon, CEDEX 08, France.
Amanda J CrossDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK.
Konstantinos K TsilidisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK.
Elio RiboliDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
Centre International de Recherche sur le Cancer · FRUniversity of Oxford · GBImperial College London · GBCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESGerman Institute of Human Nutrition · DEHellenic Health Foundation · GRPiedmont Reference Center for Epidemiology and Cancer Prevention · ITAzienda Usl 8 Arezzo · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Cancer Research Center · DEGobierno del Principado de Asturias · ESHeidelberg University · DEInstitut Català d'Oncologia · ESInstituto Murciano de Investigación Biosanitaria · ESMRC Epidemiology Unit · GBNational and Kapodistrian University of Athens · GRNational Institute for Public Health and the Environment · NLNavarre Institute of Health Research · ESUniversity of Cambridge · GB

Funding

Cancer Research UK 14136Cancer Research UK 16491Cancer Research UK 19170Cancer Research UK C8221/A19170Medical Research Council 1000143Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1World Health Organization 001
6 · The paper itself

Abstract

backgroundLittle is known about how pre-diagnostic metabolites in blood relate to risk of prostate cancer. We aimed to investigate the prospective association between plasma metabolite concentrations and risk of prostate cancer overall, and by time to diagnosis and tumour characteristics, and risk of death from prostate cancer.

methodsIn a case-control study nested in the European Prospective Investigation into Cancer and Nutrition, pre-diagnostic plasma concentrations of 122 metabolites (including acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose and sphingolipids) were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit) and compared between 1077 prostate cancer cases and 1077 matched controls. Risk of prostate cancer associated with metabolite concentrations was estimated by multi-variable conditional logistic regression, and multiple testing was accounted for by using a false discovery rate controlling procedure.

resultsSeven metabolite concentrations, i.e. acylcarnitine C18:1, amino acids citrulline and trans-4-hydroxyproline, glycerophospholipids PC aa C28:1, PC ae C30:0 and PC ae C30:2, and sphingolipid SM (OH) C14:1, were associated with prostate cancer (p < 0.05), but none of the associations were statistically significant after controlling for multiple testing. Citrulline was associated with a decreased risk of prostate cancer (odds ratio (OR

conclusionsSeveral metabolites, i.e. C18:1, citrulline, trans-4-hydroxyproline, three glycerophospholipids and SM (OH) C14:1, might be related to prostate cancer. Analyses by time to diagnosis indicated that citrulline may be a marker of subclinical prostate cancer, while other metabolites might be related to aetiology. Several glycerophospholipids were inversely related to advanced stage disease. More prospective data are needed to confirm these associations.

Indexed as

AgedBiomarkersCase-Control StudiesCohort StudiesFollow-Up StudiesHumansLogistic ModelsMaleMass SpectrometryMiddle AgedNutritional StatusOdds RatioProspective StudiesProstatic NeoplasmsBiomarkersAcylcarnitinesAmino acidsBiogenic aminesEuropean Prospective Investigation into Cancer and Nutrition (EPIC)GlycerophospholipidsHexoseMass spectrometryMetabolomicsProspective studyProstate cancer riskSphingolipids

Identifiers

PMID28676103
PMCPMC5497352
OpenAlexW2672967498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.